Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN).

Full DD Report for SUPN

You must become a subscriber to view this report.


Recent News from (NASDAQ: SUPN)

FDA OKs Supernus Pharma's Oxtellar XR as monotherapy for partial-onset seizures
The FDA approves Supernus Pharmaceuticals' (NASDAQ: SUPN ) marketing application to use Oxtellar XR (oxcarbazepine) extended-release tablets as monotherapy to treat partial-onset seizures in patients at least six years old. More news on: Supernus Pharmaceuticals, Inc., Healthcare stocks ...
Source: SeekingAlpha
Date: December, 14 2018 16:11
Supernus Announces FDA Approval of sNDA to Expand Oxtellar XR® Label to Include Monotherapy
ROCKVILLE, Md., Dec. 14, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASADQ: SUPN) announced today that the United States Food and Drug Administration (FDA) has approved the Company’s supplemental new drug application (sNDA) for Oxtellar XR ® . The application reque...
Source: GlobeNewswire
Date: December, 14 2018 16:02
Supernus Succeeds In Phase 3, But Could Face An Uphill Battle
Recently, Supernus ( SUPN ) announced results from two phase 3 studies treating patients with ADHD using SPN-812. Both studies met the primary endpoint; however, the drug didn't end up being superior to generic alternatives in terms of efficacy. There are still two positives from these s...
Source: SeekingAlpha
Date: December, 07 2018 10:54
Supernus to Present at Three November Healthcare Conferences
ROCKVILLE, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Company's management will present an ov...
Source: GlobeNewswire
Date: November, 07 2018 16:38
Supernus Pharmaceuticals' (SUPN) CEO, Jack Khattar on Q3 2018 Results - Earnings Call Transcript
Supernus Pharmaceuticals Inc. (SUPN) Q3 2018 Earnings Conference Call November 7, 2018 9:00 am ET Executives Jack Khattar - President, Chief Executive Officer Gregory Patrick - Chief Financial Officer Peter Vozzo - Westwicke Partners Analysts David Steinberg - Jefferies A...
Source: SeekingAlpha
Date: November, 07 2018 13:16
Supernus Pharmaceuticals beats by $0.13, beats on revenue
Supernus Pharmaceuticals (NASDAQ: SUPN ): Q3 GAAP EPS of $0.52 beats by $0.13 . Revenue of $103M (+28.1% Y/Y) beats by $2.29M . Press Release More news on: Supernus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 06 2018 16:34
Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue
Total revenue of $103.0 million, a 28% increase over 2017 Net product sales of $100.2 million, a 28% increase over 2017 Operating earnings of $37.5 million, a 68% increase over 2017 Diluted earnings per share (GAAP) of $0.52, a 79% increase over 2017 Data from first three Phase III SPN...
Source: GlobeNewswire
Date: November, 06 2018 16:15
Notable earnings after Tuesday's close
ACAD , AAXN , AIZ , APEI , ASH , BEL , BOLD , BWXT , CHUY , COHR , CPE , CSLT , CUTR , CWH , DAR , DATA , DIOD , DK , DOOR , DPLO , DVN , DXC , DXCM , EGN , ENLC , ENLK , ENPH , ETSY , EVH , EVRI , FANG , FIVN , FTK , FTR , G , GDDY , GHDX , GLUU , HAL...
Source: SeekingAlpha
Date: November, 05 2018 17:35
Supernus to Host Third Quarter 2018 Earnings Conference Call
ROCKVILLE, Md., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to repo...
Source: GlobeNewswire
Date: October, 24 2018 16:30
SMID Cap Growth Strategy Q3 2018 Commentary
This commentary reviews the previous quarter and discusses our outlook and investment approach for the SMID Cap Growth strategy in the coming Read more ...
Source: SeekingAlpha
Date: October, 23 2018 03:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0845.8548.2048.27545.80879,311
2018-05-1758.4556.5058.8055.951,135,878
2017-03-1027.3526.4027.4526.2571,484
2017-03-0927.8527.3528.07927.05595,080
2017-03-0826.5527.8028.5026.401,022,626

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14212,284266,81279.5631Short
2018-12-13125,808178,64170.4250Short
2018-12-1259,06897,76360.4196Short
2018-12-11125,685189,95466.1660Short
2018-12-1094,987210,85345.0489Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SUPN.


About Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Logo for Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: SUPN)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 11 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 20 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 05 2018

       

       


      Daily Technical Chart for (NASDAQ: SUPN)

      Daily Technical Chart for (NASDAQ: SUPN)


      Stay tuned for daily updates and more on (NASDAQ: SUPN)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: SUPN)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SUPN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SUPN and does not buy, sell, or trade any shares of SUPN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/